Company: IVHI
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0001683168-25-005573
Chunk: 23

Company: Invech Holdings, Inc.
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 8
Chunk 23
---
 and development of the Cashsurfers business.On July 24, 2000,
the agreement was terminated because the Company was unable to raise sufficient capital required under the merger agreement and was unable
to make payment to Cashsurfers under the terms of the agreement. As a result of the merger and subsequent termination was dilution of
stock ownership percentage for our existing shareholders, increased debt, and loss of our business model.

 9 

On October 5, 2000, the Company entered into an
Acquisition Agreement with UWANTCASH.com, Inc. whereby the Company acquired 100% of the issued and outstanding common and preferred shares
of UWANTCASH.com, Inc. in exchange for five million shares of common stock in IVHI. The acquisition agreement was terminated on December
6, 2000. The Company has no operations at that time. As a result of the termination of a second merger within a six-month period, our
stock was further diluted, and our debt increased because we had no operations.

In 2001 the Company effected a 1 for 10 reverse
stock split and on May 15, 2002, the Company entered into an agreement to acquire the Access Network Limited subsidiary of VOIP Telecom,
Inc., in exchange for the issuance of 8,000,000 shares to shareholders and owners of Access stock and an additional 4,000,000 shares to
Keppel Corp. to extinguish a debt due by Access to Keppel. In addition, IVHI issued 2,00,000 shares as a finder’s fee. Shortly after,
the Company completed a rescission agreement whereby the acquisition was cancelled. All company shares issued for debt settlements were
cancelled.

On March 17, 2003, the Company acquired
the majority interest in Hubei Pharmaceutical Co. Ltd. The Company issued 22,000,000 common shares resulting in a change in control.

On September 10th, 2004, the Company
entered into material agreement, to sell its 57.14% controlling interest in the Hubei Pharmaceutical Co. Ltd. At that time the Company
was engaged in the acquisition and vertical integration of operating subsidiaries and controlling joint venture interests in China to
include all facets of pharmaceutical life sciences from raw materials through dosage form production and distribution. In October 2005,
the Company terminated its participation in the Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd. joint venture in Hubei Province